Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTFE9Y)

• Drug Name: AFN-1252 Drug Info
• Synonyms: API-1252; API-1401; Antibacterial therapeutics, Affinium; Antibacterials, Affinium; Bacterial fatty acid biosynthesis inhibitors, Affinium; Galapagos program, Affinium; Antibacterial therapeutics, Affinium/GSK; Antibacterials, Affinium/GSK; FabI inhibitors (antibacterial), Affinium; AFN-1252 (oral, bacterial infection); AFN-1252 (oral, bacterial infection), Affinium

Indication

Disease Entry	ICD 11	Status	REF
Staphylococcus infection	1B5Y	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 10407120
  CAS Number: CAS 620175-39-5
  TTD Drug ID: DMTFE9Y

Molecule-Related Drug Atlas

Drug(s) Targeting Staphylococcus Enoyl ACP reductase (Stap-coc fabI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CG-400549	DMFAKGR	Bacterial infection	1A00-1C4Z	Phase 2	[2]
Afabicin	DMFO2G5	Acute bacterial skin infection	1C41	Phase 2	[3]
MUT-056399	DMC3NSK	Methicillin-resistant staphylococci infection	1A00-1A09	Preclinical	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Staphylococcus Enoyl ACP reductase (Stap-coc fabI)	TTZBRVL	FABI_STAA8	Inhibitor	[1]

References

• [1] Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics. J Chemother. 2013 Feb;25(1):32-5.
• [2] In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob Agents Chemother. 2007 Jul;51(7):2591-3.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob Agents Chemother. 2011 Oct;55(10):4692-7.